Applied Therapeutics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Applied Therapeutics stock.
View analyst ratings for Applied Therapeutics or view top-rated stocks.

Wall Street analysts have given Applied Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Applied Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Applied Therapeutics.

Applied Therapeutics, Inc. (NASDAQ:APLT) released its earnings results on Monday, May, 10th. The company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.01.
View Applied Therapeutics' earnings history.

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APLT shares have decreased by 19.9% and is now trading at $23.69.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued 1 year target prices for Applied Therapeutics' shares. Their forecasts range from $35.00 to $85.00. On average, they expect Applied Therapeutics' share price to reach $54.67 in the next twelve months. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for Applied Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Applied Therapeutics include ALX Oncology (ALXO), FibroGen (FGEN), Morphic (MORF), Global Blood Therapeutics (GBT), Centessa Pharmaceuticals (CNTA), Revance Therapeutics (RVNC), Nuvation Bio (NUVB), Xencor (XNCR), Prothena (PRTA), Organogenesis (ORGO), Zentalis Pharmaceuticals (ZNTL), Deciphera Pharmaceuticals (DCPH), Ligand Pharmaceuticals (LGND), Amarin (AMRN) and Seres Therapeutics (MCRB).
View all of APLT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS) and Raytheon Technologies (RTX).

(APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Applied Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (8.66%), BlackRock Inc. (4.63%), Knoll Capital Management LLC (3.93%), Franklin Resources Inc. (2.88%), Rock Springs Capital Management LP (2.69%) and Emerald Mutual Fund Advisers Trust (2.48%). Company insiders that own Applied Therapeutics stock include Charles Silberstein, Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends for Applied Therapeutics.

APLT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Citigroup Inc., and Alliancebernstein L.P.. Company insiders that have sold Applied Therapeutics company stock in the last year include Charles Silberstein, Leslie D Funtleyder, Riccardo Perfetti, and Shoshana Shendelman.
View insider buying and selling activity for Applied Therapeutics or view top insider-selling stocks.

APLT stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Franklin Resources Inc., Knoll Capital Management LLC, BlackRock Inc., Point72 Asset Management L.P., Bamco Inc. NY, Emerald Mutual Fund Advisers Trust, and DSAM Partners London Ltd. Company insiders that have bought Applied Therapeutics stock in the last two years include Real Estate Equitie Alexandria, and Stacy J Kanter.
View insider buying and selling activity for Applied Therapeutics or or view top insider-buying stocks.

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APLT stock can currently be purchased for approximately $23.69.

Applied Therapeutics has a market capitalization of $617.86 million. The company earns $-93,960,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

Applied Therapeutics employs 24 workers across the globe.

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

Applied Therapeutics is headquartered at 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173.

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]